TNFi* follow-up year group 0.33 |
TNFi use vs. no | | |
FU year 2 | 1.03 (0.29, 3.70) | 0.96 |
FU year 2.1–3.5 | 0.27 (0.08, 0.94) | 0.04 |
FU year 3.6–5.9 | 0.59 (0.19, 1.82) | 0.36 |
FU year 6– | 0.87 (0.27, 2.82) | 0.82 |
TNFi* NSAID 0.01 |
TNFi use vs. no | | |
NSAID use | 0.31 (0.13, 0.75) | 0.01 |
No NSAID use | 1.23 (0.41, 3.66) | 0.71 |
Baseline mSASSS | 1.01 (1.00, 1.03) | 0.03 |
Disease duration >10 years | 2.61 (1.56, 4.38) | <0.001 |
Male gender | 2.57 (1.43, 4.65) | 0.002 |
Education > college | 0.81 (0.43, 1.52) | 0.51 |
Current smoking | 2.47 (1.22, 4.97) | 0.01 |
# Comorbidity ≥1 | 1.28 (0.77, 2.14) | 0.34 |
First available BASDAI ≥40 | 0.96 (0.56, 1.64) | 0.88 |
First available BASFI ≥40 | 1.17 (0.63, 2.18) | 0.62 |
Baseline CRP high | 1.30 (0.80, 2.11) | 0.29 |